Benzinga | Nov 8, 2021 06:15AM EST

Morgan Stanley Downgrades bluebird bio to Underweight, Announces $11 Price Target

Morgan Stanley analyst Matthew Harrison downgrades bluebird bio (NASDAQ:BLUE) from Equal-Weight to Underweight and announces $11 price target.